Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia.

Carter MJ, Dahal LN, Cleary KLS, Marshall MJE, French RR, Beers SA, Cragg MS.

Methods Mol Biol. 2019;1881:173-184. doi: 10.1007/978-1-4939-8876-1_14.

PMID:
30350206
2.

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.

Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O'Brien L, Mockridge CI, French RR, Duriez P, Douglas LR, Pearson AR, Cragg MS, Tews I, Glennie MJ, White AL.

Cancer Cell. 2018 Apr 9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22.

3.

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.

Turaj AH, Cox KL, Penfold CA, French RR, Mockridge CI, Willoughby JE, Tutt AL, Griffiths J, Johnson PWM, Glennie MJ, Levy R, Cragg MS, Lim SH.

Sci Rep. 2018 Feb 2;8(1):2278. doi: 10.1038/s41598-018-20656-y.

4.

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, Rösner T, Dechant M, Derer S, Klausz K, Kellner C, Schwanbeck R, French RR, Tipton TRW, Cragg MS, Schewe DM, Peipp M, Leusen JHW, Valerius T.

Br J Haematol. 2018 May;181(3):413-417. doi: 10.1111/bjh.14624. Epub 2017 Apr 27. No abstract available.

PMID:
28449349
5.

OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.

Lai C, August S, Albibas A, Behar R, Cho SY, Polak ME, Theaker J, MacLeod AS, French RR, Glennie MJ, Al-Shamkhani A, Healy E.

Clin Cancer Res. 2016 Aug 15;22(16):4236-48. doi: 10.1158/1078-0432.CCR-15-2614. Epub 2016 Mar 31.

6.

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, Hussain K, Vaughan AT, Dou L, Earley A, Dahal LN, Lu C, Dunscombe M, Chan HT, Penfold CA, Kim JH, Potter EA, Mockridge CI, Roghanian A, Oldham RJ, Cox KL, Lim SH, Teige I, Frendéus B, Glennie MJ, Beers SA, Cragg MS.

J Immunol. 2015 Dec 1;195(11):5503-16. doi: 10.4049/jimmunol.1402988. Epub 2015 Oct 28.

7.

Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo.

Tipton TR, Mockridge CI, French RR, Tutt AL, Cragg MS, Beers SA.

Blood. 2015 Dec 10;126(24):2643-5. doi: 10.1182/blood-2015-09-671339. Epub 2015 Oct 22. No abstract available.

8.

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.

Tipton TR, Roghanian A, Oldham RJ, Carter MJ, Cox KL, Mockridge CI, French RR, Dahal LN, Duriez PJ, Hargreaves PG, Cragg MS, Beers SA.

Blood. 2015 Mar 19;125(12):1901-9. doi: 10.1182/blood-2014-07-588376. Epub 2015 Jan 28.

9.

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.

White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, Potter EA, Ardern-Jones MR, Verbeek JS, Johnson PW, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.

Cancer Cell. 2015 Jan 12;27(1):138-48. doi: 10.1016/j.ccell.2014.11.001. Epub 2014 Dec 11.

10.

Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.

Hussain K, Hargreaves CE, Roghanian A, Oldham RJ, Chan HT, Mockridge CI, Chowdhury F, Frendéus B, Harper KS, Strefford JC, Cragg MS, Glennie MJ, Williams AP, French RR.

Blood. 2015 Jan 1;125(1):102-10. doi: 10.1182/blood-2014-08-593061. Epub 2014 Nov 13.

11.

Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.

White AL, Dou L, Chan HT, Field VL, Mockridge CI, Moss K, Williams EL, Booth SG, French RR, Potter EA, Butts C, Al-Shamkhani A, Cragg MS, Verbeek JS, Johnson PW, Glennie MJ, Beers SA.

J Immunol. 2014 Aug 15;193(4):1828-35. doi: 10.4049/jimmunol.1303204. Epub 2014 Jul 14.

12.

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.

Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ.

J Immunol. 2013 Oct 15;191(8):4130-40. doi: 10.4049/jimmunol.1301430. Epub 2013 Sep 11.

13.

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

King BC, Hamblin AD, Savage PM, Douglas LR, Hansen TH, French RR, Johnson PW, Glennie MJ.

Cancer Immunol Immunother. 2013 Jun;62(6):1093-105. doi: 10.1007/s00262-013-1408-8. Epub 2013 Apr 19.

14.

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.

White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ.

Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31. Review.

PMID:
23543215
15.

Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).

Williams EL, Tutt AL, French RR, Chan HT, Lau B, Penfold CA, Mockridge CI, Roghanian A, Cox KL, Verbeek JS, Glennie MJ, Cragg MS.

Eur J Immunol. 2012 Aug;42(8):2109-20. doi: 10.1002/eji.201142302. Epub 2012 Jul 4.

16.

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, Beers SA, French RR, Cox KL, Davies AJ, Potter KN, Mockridge CI, Oscier DG, Johnson PW, Cragg MS, Glennie MJ.

Blood. 2011 Sep 1;118(9):2530-40. doi: 10.1182/blood-2011-01-330357. Epub 2011 Jul 18.

17.

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.

J Immunol. 2011 Aug 15;187(4):1754-63. doi: 10.4049/jimmunol.1101135. Epub 2011 Jul 8.

18.

CD20 as a target for therapeutic type I and II monoclonal antibodies.

Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ.

Semin Hematol. 2010 Apr;47(2):107-14. doi: 10.1053/j.seminhematol.2010.01.001. Review.

PMID:
20350657
19.

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PW, Verbeek JS, Glennie MJ, Cragg MS.

Blood. 2010 Jun 24;115(25):5191-201. doi: 10.1182/blood-2010-01-263533. Epub 2010 Mar 11.

20.

Anti-CD20 monoclonal antibodies: historical and future perspectives.

Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS.

Haematologica. 2010 Jan;95(1):135-43. doi: 10.3324/haematol.2008.001628. Epub 2009 Sep 22. Review.

21.

Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.

Gray JC, French RR, James S, Al-Shamkhani A, Johnson PW, Glennie MJ.

Eur J Immunol. 2008 Sep;38(9):2499-511. doi: 10.1002/eji.200838208.

22.

CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses.

Castro FV, Tutt AL, White AL, Teeling JL, James S, French RR, Glennie MJ.

Eur J Immunol. 2008 Aug;38(8):2263-73. doi: 10.1002/eji.200838302.

23.

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.

Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, Ahuja A, Shlomchik MJ, Cragg MS, Glennie MJ.

Blood. 2008 Nov 15;112(10):4170-7. doi: 10.1182/blood-2008-04-149161. Epub 2008 Jun 26.

24.

Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.

Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham GK, Glennie MJ, Cragg MS.

J Biol Chem. 2008 Jun 20;283(25):16971-84. doi: 10.1074/jbc.M708459200. Epub 2008 Apr 21.

25.

Mechanisms of killing by anti-CD20 monoclonal antibodies.

Glennie MJ, French RR, Cragg MS, Taylor RP.

Mol Immunol. 2007 Sep;44(16):3823-37. Review.

PMID:
17768100
26.

Immunotherapy with antibody-targeted HLA class I complexes: results of in vivo tumour cell killing and therapeutic vaccination.

Savage P, Dyson J, Milrain M, Mathews D, King B, Chan HT, Barber L, Epenetos A, Ogg G, McMichael A, Glennie MJ, French RR.

Tumour Biol. 2007;28(4):205-11. Epub 2007 Aug 20.

PMID:
17709989
27.

Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.

French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW, Tutt AL, Al-Shamkhani A, Glennie MJ.

Blood. 2007 Jun 1;109(11):4810-5. Epub 2007 Feb 20.

28.

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG.

J Immunol. 2006 Jul 1;177(1):362-71.

29.

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells.

Cragg MS, Bayne MB, Tutt AL, French RR, Beers S, Glennie MJ, Illidge TM.

Blood. 2004 Oct 15;104(8):2540-2. Epub 2004 Jun 22.

30.

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ.

Blood. 2004 Sep 15;104(6):1793-800. Epub 2004 Jun 1.

31.

CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, Glennie MJ, Cragg MS.

Cancer Res. 2003 Sep 1;63(17):5480-9.

32.

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.

Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, French RR, Glennie MJ.

Blood. 2003 Feb 1;101(3):1045-52. Epub 2002 Sep 19.

33.

A supramolecular enzyme model catalyzing the central cleavage of carotenoids.

French RR, Holzer P, Leuenberger M, Nold MC, Woggon WD.

J Inorg Biochem. 2002 Feb;88(3-4):295-304.

PMID:
11897343
34.

T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.

Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ.

J Immunol. 2002 Mar 15;168(6):2720-8.

36.

How to make bispecific antibodies.

French RR.

Methods Mol Med. 2000;40:333-9. doi: 10.1007/978-1-59259-076-6_26.

PMID:
21337104
37.

The application of monoclonal antibodies in the treatment of lymphoma.

Glennie MJ, Honeychurch J, French RR, Tutt AL.

Methods Mol Med. 2000;40:85-97. doi: 10.1385/1-59259-076-4:85.

PMID:
21337085
38.

Signaling antibodies in cancer therapy.

Cragg MS, French RR, Glennie MJ.

Curr Opin Immunol. 1999 Oct;11(5):541-7. Review.

PMID:
10508709
39.

The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma.

Illidge TM, Cragg MS, McBride HM, French RR, Glennie MJ.

Blood. 1999 Jul 1;94(1):233-43.

40.

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

French RR, Chan HT, Tutt AL, Glennie MJ.

Nat Med. 1999 May;5(5):548-53.

PMID:
10229232
41.

Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells.

Cragg MS, Zhang L, French RR, Glennie MJ.

Br J Cancer. 1999 Feb;79(5-6):850-7.

42.
43.

Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.

Tutt AL, French RR, Illidge TM, Honeychurch J, McBride HM, Penfold CA, Fearon DT, Parkhouse RM, Klaus GG, Glennie MJ.

J Immunol. 1998 Sep 15;161(6):3176-85.

44.

Production of bispecific and trispecific F(ab)2 and F(ab)3 antibody derivatives.

French RR.

Methods Mol Biol. 1998;80:121-34. No abstract available.

PMID:
9664369
45.

Response of B-cell lymphoma to a combination of bispecific antibodies and saporin.

French RR, Bell AJ, Hamblin TJ, Tutt AL, Glennie MJ.

Leuk Res. 1996 Jul;20(7):607-17.

PMID:
8795695
46.

The development of anti-CD79 monoclonal antibodies for treatment of B-cell neoplastic disease.

Zhang L, French RR, Chan HT, O'Keefe TL, Cragg MS, Power MJ, Glennie MJ.

Ther Immunol. 1995 Aug;2(4):191-202.

PMID:
9358611
47.

Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin.

French RR, Hamblin TJ, Bell AJ, Tutt AL, Glennie MJ.

Lancet. 1995 Jul 22;346(8969):223-4.

PMID:
7542357
48.

Measurement of kinetic binding constants of a panel of anti-saporin antibodies using a resonant mirror biosensor.

George AJ, French RR, Glennie MJ.

J Immunol Methods. 1995 Jun 14;183(1):51-63.

PMID:
7602139
49.

Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.

French RR, Penney CA, Browning AC, Stirpe F, George AJ, Glennie MJ.

Br J Cancer. 1995 May;71(5):986-94.

50.

Mechanisms in removal of tumor by antibody.

Stevenson GT, Bell AJ, Evans TR, French RR, Glennie MJ, Hamblin TJ, Kan KS, Mead GM.

Cell Biophys. 1994;24-25:45-50.

PMID:
7736539

Supplemental Content

Loading ...
Support Center